7 |
General |
Vaccines |
2021 |
Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies |
|
|
6 |
ADC (Nterm) |
mAbs |
2021 |
N-terminal selective conjugation method widens the therapeutic window of antibody–drug conjugates by improving tolerability and stability |
|
|
5 |
ABL503 |
JITC |
2021 |
Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade |
|
|
4 |
4-1BB Platform |
Science Advances |
2021 |
B7-H3×4-1BB bispecific antibody augments antitumor immunity by enhancing terminally differentiated CD8+tumor-infiltrating lymphocytes |
|
|
3 |
ABL001 |
BMB Reports |
2020 |
Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer |
|
|
2 |
ABL001 |
Int J Mol Sci |
2020 |
ABL001, a bispecific antibody targeting VEGF and DLL4, with chemotherapy, synergistically inhibits tumor progression in xenograft models |
|
|
1 |
ABL001 |
mAbs |
2016 |
Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis |
|
|